- $622.96m
- $321.58m
- $417.21m
- 88
- 60
- 90
- 93
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 196 | 283 | 392 | 433 | 417 |
Cost of Revenue | |||||
Gross Profit | 118 | 194 | 289 | 329 | 326 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 264 | 324 | 442 | 516 | 404 |
Operating Profit | -68.5 | -40.8 | -50.8 | -82.9 | 13 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -75.2 | -49.8 | -51.9 | -77.7 | 24.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -75.6 | -50.6 | -52.8 | -79.6 | 22 |
Net Income Before Extraordinary Items | |||||
Net Income | -75.6 | -50.6 | -52.8 | -79.6 | 22 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -75.6 | -50.6 | -52.8 | -79.6 | 22 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.441 | -0.318 | -0.371 | -0.476 | 0.16 |
Dividends per Share |